Where do we stand with antithrombotic prophylaxis in patients with COVID-19?

Thromb Res. 2020 Jul:191:29. doi: 10.1016/j.thromres.2020.04.023. Epub 2020 Apr 20.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Betacoronavirus
  • COVID-19
  • Coronavirus Infections
  • Critical Illness*
  • Fibrinolytic Agents*
  • Humans
  • Incidence
  • Intensive Care Units
  • Pandemics
  • Pneumonia, Viral
  • SARS-CoV-2

Substances

  • Fibrinolytic Agents